Anti-neutrophil Cytoplasmic Antibody-associated VasculitisPhase 1NCT06004947
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
A Phase 1 study testing CCX168, Midazolam and Celecoxib in people with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis, run by Amgen at 1 site in United States.
Trial summary
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- What is being tested?
- CCX168, Midazolam and Celecoxib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- 14 Jan 2016to 10 Jun 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male or female participants, aged 18-55 years inclusive, who are in generally good health as judged by the Investigator, whose body mass index is 19.0 to 32.0 kg/m^2 inclusive;
- Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;
- Negative result of the human immunodeficiency virus screen, the hepatitis B screen, and the hepatitis C screen;
- Judged to be healthy by the Investigator, based on medical history, physical examination (including electrocardiogram, and clinical laboratory assessments. Participants with clinical laboratory values that are outside of normal limits and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance may be entered into the study;
- Female participants of childbearing potential, or male participants with partners of childbearing potential may participate if adequate contraception is used during, and for at least 90 days after, any administration of study medication.
Who cannot join
- Pregnant or breastfeeding;
- Used a prescription and/or over-the-counter medication, with the exception of ibuprofen, hormonal contraceptives, and multi-vitamins, within 14 days prior to check-in; herbal supplements must be stopped 7 days prior to check-in;
- For at least 14 days prior to check-in and throughout the blood sample collection period, participants will not be allowed to eat any food or drink any beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats; strenuous exercise must be stopped 4 days prior to check-in;
- History within the three months prior to check-in of use of tobacco and/or nicotine containing products;
- History within one year prior to check-in of illicit drug use;
- History of alcohol abuse at any time in the past;
Show all 16Show fewer
- Has a history or presence of any form of cancer within the 5 years prior to check-in, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;
- History or presence of unexplained syncope or family history of sudden death, or any medical condition or disease which, in the opinion of the Investigator, may place the participant at unacceptable risk for study participation;
- Donated or lost more than 350 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of dosing;
- Participant's hemoglobin less than 11.5 g/dL for women or less than 13.0 g/dL for men, at screening or check-in, confirmed by a repeat measurement;
- Participated in any clinical study of an investigational product within 30 days prior to dosing or within 5 half-lives after dosing;
- Participant has any evidence of hepatic disease; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin greater than 1.5 times the upper limit of normal at screening or check-in;
- Participant's white blood cell count is below the lower limit of normal at screening or check-in, confirmed by a repeat measurement;
- Participant has any evidence of renal impairment; serum creatinine greater than 1.5 times the upper limit of normal at screening or check-in;
- Participant's urine tested positive at screening and/or check-in for any of the following: opioids, amphetamines and methamphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, methylenedioxymethamphetamine (MDMA or "ecstasy"), methadone, phencyclidine, tri-cyclic antidepressants, or alcohol (Breathalyzer test allowed for alcohol).
- Participant is known as a CYP2C9 poor metabolizer.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
- Being tested
- CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
- Keywords
- Renal diseases, Atypical hemolytic uremic syndrome, Immunoglobulin A nephropathy, Complement 5a receptor (C5aR), Complement
- Medical subject headings
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Kidney Diseases, Atypical Hemolytic Uremic Syndrome, Glomerulonephritis, IGA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CCX168Drug
Administered orally.
MidazolamDrug
Administered orally.
CelecoxibDrug
Administered orally.
ItraconazoleDrug
Administered orally.
RifampicinDrug
Administered orally.
| Study group | Role | What they receive |
|---|---|---|
| Cohort A | Experimental | A single dose of 2 mg midazolam (a Cytochrome P450 [CYP]3A4 probe drug) and a single dose of 200 mg celecoxib (a CYP2C9 probe drug) will be given orally concurrently on Day 1 and Day 13. On Day 3 through Day 18, CCX168 will be given orally at 30 mg twice daily (b.i.d.), and a single dose of 30 mg CCX168 will be given in the morning on Day 19. On Day 16 through Day 19, a once daily (q.d.) dose of 200 mg itraconazole (a CYP3A4 inhibitor) will be given orally. Receives: Drug: CCX168; Drug: Midazolam; Drug: Celecoxib; Drug: Itraconazole |
| Cohort B | Experimental | A single dose of 30 mg CCX168 will be given on Day 1 and Day 14, while rifampicin (a CYP3A4 inducer) will be given at 600 mg once daily from Day 4 through Day 17. Receives: Drug: CCX168; Drug: Rifampicin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cohort A: Maximum Plasma Concentration (Cmax) of Midazolam
Measured: Up to Day 13
Cohort A: Cmax of Celecoxib
Measured: Up to Day 13
Cohort A: Time of Cmax (Tmax) of Midazolam
Measured: Up to Day 13
Cohort A: Tmax of Celecoxib
Measured: Up to Day 13
Cohort A: Area under the plasma concentration-time curve (AUC) from Time 0 to infinity of Midazolam
Measured: Up to Day 13
Cohort A: AUC from Time 0 to infinity of Celecoxib
Measured: Up to Day 13
Cohort A: Apparent Terminal Half Life of Midazolam
Measured: Up to Day 13
Cohort A: Apparent Terminal Half Life of Celecoxib
Measured: Up to Day 13
Cohort A: Cmax of CCX168
Measured: Day 15 up to Day 19
Cohort A: Tmax of CCX168
Measured: Day 15 up to Day 19
Cohort A: AUC Over the Dosing Interval of CCX168
Measured: Day 15 up to Day 19
Cohort B: Cmax of CCX168
Measured: Up to Day 14
Cohort B: Tmax of CCX168
Measured: Up to Day 14
Cohort B: AUC from Time 0 to infinity of CCX168
Measured: Up to Day 14
Cohort B: Apparent Terminal Half Life of CCX168
Measured: Up to Day 14
Secondary outcomes (3)
Number of Participants Experiencing Adverse Events (AEs)
Measured: Up to Day 29
Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters
Measured: Up to Day 19
Number of Participants Experiencing Clinically Significant Changes in Vital Sign Parameters
Measured: Up to Day 19
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2023
- Study start14 Jan 2016
- Primary completion15 Mar 2016
- Study completion10 Jun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anti-neutrophil Cytoplasmic Antibody-associated VasculitisStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06004947
- Sponsor's protocol ID
- CL008_168
- Status last verified
- Aug 2023
- First submitted
- 15 Aug 2023
- Last updated
- 22 Aug 2023
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
- ClinicalTrials.gov ID
- NCT06004947
- Acronym / sponsor ID
- CL008_168
- Keywords
- Renal diseases, Atypical hemolytic uremic syndrome, Immunoglobulin A nephropathy, Complement 5a receptor (C5aR), Complement
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 14 Jan 2016 (actual)
- Primary completion
- 15 Mar 2016 (actual)
- Study completion
- 10 Jun 2016 (actual)
- First posted
- 22 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cohort A | Experimental | Drug: CCX168, Drug: Midazolam, Drug: Celecoxib, Drug: ItraconazoleA single dose of 2 mg midazolam (a Cytochrome P450 [CYP]3A4 probe drug) and a single dose of 200 mg celecoxib (a CYP2C9 probe drug) will be given orally concurrently on Day 1 and Day 13. On Day 3 through Day 18, CCX168 will be given orally at 30 mg twice daily (b.i.d.), and a single dose of 30 mg CCX168 will be given in the morning on Day 19. On Day 16 through Day 19, a once daily (q.d.) dose of 200 mg itraconazole (a CYP3A4 inhibitor) will be given orally. |
| Cohort B | Experimental | Drug: CCX168, Drug: RifampicinA single dose of 30 mg CCX168 will be given on Day 1 and Day 14, while rifampicin (a CYP3A4 inducer) will be given at 600 mg once daily from Day 4 through Day 17. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male or female participants, aged 18-55 years inclusive, who are in generally good health as judged by the Investigator, whose body mass index is 19.0 to 32.0 kg/m^2 inclusive;
- Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;
- Negative result of the human immunodeficiency virus screen, the hepatitis B screen, and the hepatitis C screen;
- Judged to be healthy by the Investigator, based on medical history, physical examination (including electrocardiogram, and clinical laboratory assessments. Participants with clinical laboratory values that are outside of normal limits and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance may be entered into the study;
- Female participants of childbearing potential, or male participants with partners of childbearing potential may participate if adequate contraception is used during, and for at least 90 days after, any administration of study medication.
Key exclusion criteria (16 listed)
- Pregnant or breastfeeding;
- Used a prescription and/or over-the-counter medication, with the exception of ibuprofen, hormonal contraceptives, and multi-vitamins, within 14 days prior to check-in; herbal supplements must be stopped 7 days prior to check-in;
- For at least 14 days prior to check-in and throughout the blood sample collection period, participants will not be allowed to eat any food or drink any beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats; strenuous exercise must be stopped 4 days prior to check-in;
- History within the three months prior to check-in of use of tobacco and/or nicotine containing products;
- History within one year prior to check-in of illicit drug use;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CCX168Administered orally. | Drug | Cohort A, Cohort B |
| MidazolamAdministered orally. | Drug | Cohort A |
| CelecoxibAdministered orally. | Drug | Cohort A |
| ItraconazoleAdministered orally. | Drug | Cohort A |
| RifampicinAdministered orally. | Drug | Cohort B |
Primary outcome
Cohort A: Maximum Plasma Concentration (Cmax) of Midazolam
Time frame: Up to Day 13
Cohort A: Cmax of Celecoxib
Time frame: Up to Day 13
Cohort A: Time of Cmax (Tmax) of Midazolam
Time frame: Up to Day 13
Cohort A: Tmax of Celecoxib
Time frame: Up to Day 13
Cohort A: Area under the plasma concentration-time curve (AUC) from Time 0 to infinity of Midazolam
Time frame: Up to Day 13
Cohort A: AUC from Time 0 to infinity of Celecoxib
Time frame: Up to Day 13
Cohort A: Apparent Terminal Half Life of Midazolam
Time frame: Up to Day 13
Cohort A: Apparent Terminal Half Life of Celecoxib
Time frame: Up to Day 13
Cohort A: Cmax of CCX168
Time frame: Day 15 up to Day 19
Cohort A: Tmax of CCX168
Time frame: Day 15 up to Day 19
Cohort A: AUC Over the Dosing Interval of CCX168
Time frame: Day 15 up to Day 19
Cohort B: Cmax of CCX168
Time frame: Up to Day 14
Cohort B: Tmax of CCX168
Time frame: Up to Day 14
Cohort B: AUC from Time 0 to infinity of CCX168
Time frame: Up to Day 14
Cohort B: Apparent Terminal Half Life of CCX168
Time frame: Up to Day 14
3 secondary outcomes
Number of Participants Experiencing Adverse Events (AEs)
Time frame: Up to Day 29
Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters
Time frame: Up to Day 19
Number of Participants Experiencing Clinically Significant Changes in Vital Sign Parameters
Time frame: Up to Day 19
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2023.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Related trials for Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
Active, not recruitingPhase 2
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
RecruitingPhase 1/2
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Systemic Sclerosis, Idiopathic Inflammatory Myopathies
RecruitingObservational study
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Takayasu's Arteritis, Giant Cell Arteritis
Not yet recruitingPhase 2
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MD study director
Amgen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CCX168, Midazolam and Celecoxib in people with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis, run by Amgen at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cohort A: Maximum Plasma Concentration (Cmax) of Midazolam (time frame: Up to Day 13). The study lists 15 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2023; AzTrials last refreshed its copy on 8 Nov 2026.